Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease

Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease

The purpose of this study is to understand the effect of vascular endothelial growth factor tyrosine kinase (VEGF) inhibitor, immune checkpoint-inhibitor (ICI), and combination treatment on blood pressure and blood vessel function.

Inclusion Criteria:

• Male or female, age 40 - 75 years old
• Diagnosis of cancer
• Receiving VEGF inhibitor, ICI, or combination (VEGF inhibitor + ICI or combination ICI) treatment, or not receiving any treatment.
• Normal blood pressure or blood pressure treated to < 140/90 mm Hg with ≤2 antihypertensive medications

Exclusion Criteria:

• Presence of peripheral artery disease
• History of a heart attack within 1 year
• History of a stroke within 1 year
• Diabetes
• Life expectancy < 3 months
• Women who are pregnant
• Women who are nursing